ClinicalTrials.gg
RecruitingNCT07093502Updated Jul 30, 2025

Establishment of a Classification System and Postoperative Risk Warning Model for Patients Undergoing Bariatric Metabolic Surgery for Severe Obesity

An observational study in Obesity, Bariatric Surgery and Bariatric Surgery (Sleeve Gastrectomy ), sponsored by The Third Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-07-30.

Primary conditionObesity, MorbidRegistry: ObesityReclassifiedWhy we changed it
Registry
Obesity — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity, Morbid
Why
  1. The study's title name Obesity, Morbid, a narrower term within Obesity.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Third Xiangya Hospital of Central South University · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Obesity, Morbid with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Obesity, Morbid · China.

Started
2025
with 2 others
Observational
3 of 10
1 open now
Registered
9th of 10
by date
Lead sponsor
1 of 10
The Third Xiangya Hospital of Central South University

Among the 10 studies in Obesity, Morbid with a site in China, this one is one of 3 that started in 2025, is one of 3 observational ones, and was the 9th registered.

Obesity, Morbid

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

Browse Obesity, Morbid studies →

Open to participants now

4 of the 10 studies in Obesity, Morbid with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Obesity, Morbid with a site in China, or all of them as a file.
02

Study summary

This study aims to establish a classification system for patients undergoing metabolic surgery for severe obesity by constructing a prospective cohort of 2,000 patients and collecting clinical and biological data at multiple time points before and after surgery. By analyzing clinical, laboratory, and multi-omics characteristics, the study will identify indicators associated with postoperative adverse events and develop a risk warning model using machine learning algorithms. Ultimately, an intelligent digital system will be developed based on the classification criteria and risk model, integrating surgical classification and risk alert functions to provide real-time feedback, supporting clinicians and patients in optimizing postoperative treatment and risk management.

Read the detailed description

Establishment of a Prospective Disease-Specific Follow-up Cohort of 2,000 Patients Based on the Following Inclusion and Exclusion Criteria

All participants will undergo metabolic surgery. A prospective, disease-specific follow-up cohort will be established, and baseline data will be collected. Patients will be followed up at multiple postoperative time points: days 3 and 7, and months 1, 3, 6, 12, and 24. Follow-up assessments will include the occurrence of postoperative complications and adverse events, as well as the degree of metabolic improvement and prognosis.

A multidimensional data platform will be used to integrate and analyze diverse indicators, identifying those strongly associated with postoperative adverse events. Clustering analysis will be applied to establish a classification system for patients undergoing metabolic surgery for severe obesity. Targeted assays will be performed on time-series biospecimens to identify novel risk biomarkers. A risk warning model will be constructed, validated, and evaluated. Finally, an intelligent digital system integrating patient classification and real-time risk alert functions will be developed to optimize long-term outcomes and enhance the precision and timeliness of classification and risk warning for healthcare professionals and patients.

03

Conditions studied

  • Obesity
  • Bariatric Surgery
  • Bariatric Surgery (Sleeve Gastrectomy )

Browse trials for

Keywords

  • Severe obesity
  • bariatric surgery
  • Classification System
  • Postoperative Risk Warning Model
04

In context

Obesity, Morbid Reclassified

941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.

This study's planned enrollment of 2,000 is above the median of 80 across 311 observational studies indexed under Obesity, Morbid.

Browse Obesity, Morbid studies →

Lead sponsor

The Third Xiangya Hospital of Central South University is the lead sponsor of 99 studies on the registry; 52 are open to participants now.

Compared within Obesity, Morbid, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Obesity. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing bariatric/metabolic surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who meet the clinical indications for bariatric/metabolic surgery;

    • Adults aged 18 to 50 years; ③ Stable body weight (change within ±5% over the past 3 months); ④ Undergoing either laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB).

Exclusion criteria

Exclusion Criteria:

  • ① Patients with conditions affecting the immune or metabolic systems (e.g., endocrine disorders such as untreated hypothyroidism/hyperthyroidism, cancer);

    • Patients with renal or hepatic impairment;

      • Patients who have taken medications that may affect metabolism within the past 3 months (e.g., weight-loss drugs, asthma medications, psychiatric medications, );

        • Patients who have previously undergone bariatric surgery and are undergoing revisional surgery; ⑤ Patients with psychiatric disorders, especially those with comorbid behavioral or personality disorders (e.g., binge eating disorder);

          • Patients currently participating in other clinical studies that may conflict with this study or those who refuse to sign the form.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Number of Participants Stratified into Distinct Clusters Using Unsupervised Clustering Algorithm Based on BMI, Comorbidity Count, Inflammatory Markers, and Proteomics Profiles

    Participants will be stratified at baseline using an unsupervised clustering algorithm (e.g., k-means) based on the following input variables:(1)Body mass index (BMI, kg/m²);(2)Comorbidity count (number of chronic diseases at enrollment);(3)Inflammatory markers (e.g., CRP in mg/L, IL-6 in pg/mL);(4)Proteomics features (relative expression intensity from LC-MS) The clustering procedure will produce a categorical variable assigning each participant to one of 3-5 data-driven subtypes. The total number of participants in each subtype group will be reported.

    Time frame: From enrollment to the end of follow-up at 2 years

  2. Accuracy, Sensitivity, and Specificity of the Postoperative Risk Prediction Model for Adverse Outcomes

    Model performance will be assessed for predicting postoperative adverse outcomes within 12 months after bariatric surgery. Predictors include demographic data, intraoperative parameters, early postoperative recovery data, and stratification subtype. Model discrimination will be evaluated using area under the receiver operating characteristic curve (AUC-ROC), and calibration will be assessed with calibration plots and Hosmer-Lemeshow test. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) will be reported using confusion matrix analysis in internal validation (e.g., bootstrapping or 10-fold cross-validation).

    Time frame: Up to 24 months after surgery

Secondary outcomes

  1. User Satisfaction Score of the Digital Postoperative Management System Measured by System Usability Scale (SUS)

    User experience and satisfaction with the digital management system will be evaluated using the validated 10-item System Usability Scale (SUS). SUS scores range from 0 to 100, with higher scores indicating greater usability. Both patients and clinical staff will be surveyed at 3 months post-deployment.

    Time frame: At 24 months after initiation of digital system use

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided — Undecided. Data sharing is currently under consideration. The decision will depend on institutional policy, ethical review board approval, and the establishment of appropriate data-use agreements to protect participant confidentiality.

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2035, 128 months after the start.

Of 138 non-industry observational studies under Obesity, Morbid, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 132. This study's planned 128 months is above that.

Counting every sponsor, half of 139 studies reached it within 46 months; a quarter within 16 and three quarters within 132.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2025
First posted
Jul 30, 2025
StartActual
Apr 1, 2025
Primary completionEst.
Dec 31, 2035
CompletionEst.
Dec 31, 2035
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07093502
Lead sponsor
The Third Xiangya Hospital of Central South University
Responsible party
Sponsor
First posted
Jul 30, 2025
Start date
Apr 1, 2025
Primary completion
Dec 31, 2035 (estimated)
Completion
Dec 31, 2035 (estimated)
Last update
Jul 30, 2025

Study contacts

Liyong Zhu
Contact
zly8128@csu.edu.cn
+86 13975879453

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion